Allergan, Inc. Selects Dendrite's New ScripMaxIQ Market Research/Sales Management Solution.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 22, 2003

Interactive Web-based Prescription Data Analysis Tool Delivers

Unprecedented Views of Market Trends For Actionable Intelligence 

Dendrite International, Inc. (NASDAQ: DRTE) today announced that Allergan, Inc. has purchased Dendrite's new ScripMaxIQ(TM) solution, the pharmaceutical industry's first comprehensive marketing application capable of improving the return on all channels of promotion.

It enables companies to increase sales and market share by identifying opportunities to develop powerful competitive strategies based on specific patterns of prescribing events. These events are determined through analysis of Dendrite's longitudinal prescription data--the largest and richest prescription data source available to the U.S. pharmaceutical industry.

As the first client to begin using this powerful new intelligence, Allergan has embarked on a bold new approach to marketing its products on a national basis. "We believe this data will provide a rich set of insights into the behavior of key physician segments that will enable us to sustain a real competitive advantage," said Gerry McKenzie, Allergan Vice President of Customer Operations. "We are pleased to be a frontrunner in the adoption of this new technology."

Michael Barnes, Dendrite Vice President of Business Intelligence Solutions, commented, "ScripMaxIQ enables companies to access market trends and identify prescriber behavior in order to segment physicians and tailor messages to either reinforce or change behaviors critical to brand success. Delivering these segment-specific messages to the individual physician permits companies, for the first time, to truly market to the segment of one."

Through a secure-access, web-based portal, ScripMaxIQ generates key event reports through the timely delivery of actionable information, enabling clients to make critical business decisions based on the latest physician prescribing habits and market patterns. Analyses of prescriber behavior and therapy patterns form a revolutionary new mechanism for evaluating market conditions and competitors, developing and executing short-term tactical responses, and planning long-term strategies.

"A growing number of pharmaceutical companies are transitioning from traditional data sources to longitudinal data-driven applications as a basis for conducting in-depth research and analyses," added Barnes. "Now, instead of simply receiving static reports, they can fully take advantage of this powerful emerging data source to generate their own intelligence based on specific corporate objectives and agendas."

Superior Applications

ScripMaxIQ allows users to generate reports on new therapy or brand starts, switching patterns, and dosage changes at the national, state, and MSA levels. Clients can perform detailed analyses based on distinct analytical processes by trend, product, or geography while using standard analytical templates in graph, chart, or grid formats. Additional reporting capabilities will include concomitance, persistence, and compliance analysis.

Users also have full access to Dendrite's experience and expertise in conducting analytically driven research, including consulting, defining precise metrics, and designing superior algorithms to mine data for answers to critical business questions.

Superior Design

A flexible, cost-efficient, and rapidly deployable solution, ScripMaxIQ is simple, intuitive, and easy to navigate, and does not require software installed on a user's computer. It operates under a secure environment and is driven by the industry's largest U.S. retail-based prescription database. This data, which meets HIPAA requirements, is sourced from Dendrite's Pharmacy Consortium, a group of demographically and geographically diverse U.S. retail pharmacies. Each month, Dendrite is capturing an estimated 140 million new government, cash, and third party prescriptions--providing the drug industry with the most complete and truly representative source of information.

Superior Technology

The longitudinal data that powers ScripMaxIQ is captured, stored, and processed via Dendrite's leading edge, multi-terabyte data warehouse in Chesapeake, Virginia. Using the latest Teradata technology, Dendrite acquires, purifies, conditions, standardizes, stores, and processes billions of rows of information, providing clients with unprecedented performance.

About Dendrite

Dendrite develops and delivers solutions that increase value in sales, marketing, and clinical processes for life sciences clients. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. All "outlook" information constitutes forward-looking statements. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products, our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; changes in demand for our products and services attributable to the current weakness in the economy; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; events which may affect the U.S. and world economies; our ability to manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; the potential for hostilities in the Middle East and Asia and the resulting impact on our business and the business and needs of our customers; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.